Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 27, 2022 10:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstract for Metastatic Uveal Melanoma at American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

KNOXVILLE, TN, April 27, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10, a formulation of...
February 16, 2022 09:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces Acceptance of PV-10® Metastatic Uveal Melanoma Abstract for Oral Presentation at 2022 International Society of Ocular Oncology (ISOO) Congress

KNOXVILLE, TN, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 for the treatment of...
March 21, 2019 08:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Provides Update on Metastatic Uveal Melanoma Clinical Development Program for Investigational Drug PV-10

KNOXVILLE, TN, March 21, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updates on the Company's metastatic uveal melanoma drug development program for its lead investigational...
October 24, 2018 16:15 ET | Source: Provectus Biopharmaceuticals Inc.

PROVECTUS ANNOUNCES PRESENTATION OF DATA FROM METASTATIC UVEAL MELANOMA COHORT OF PHASE 1 STUDY OF PV-10 IN LIVER CANCERS AT SMR 2018 CONGRESS

- Assessing adverse event and preliminary efficacy profiles of PV-10 as single-agent and in combination with immune checkpoint inhibition for treatment of liver metastases KNOXVILLE, TN, Oct....